Literature DB >> 7647082

An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.

A Gendron1, G Sirois, N P Nair, D Bloom, G Movin-Osswald, G Uppfeldt.   

Abstract

The tolerability and pharmacokinetics of raclopride extended release (ER) capsules have been evaluated after a single oral dose and at steady state, with 3 different daily doses in 4 male patients requiring neuroleptic treatment. In this 3-week open study, the drug was administered to patients in increasing bid doses of 8 mg, 12 mg and 16 mg, respectively, for each 1-week treatment period, following a 1-week placebo washout. With this limited number of patients, assessments of clinical chemistry, hematology, cardiovascular variables and adverse symptoms suggest that raclopride is safe and well-tolerated in the group studied. The administration of repeated doses of raclopride showed linear pharmacokinetics based on parameter values which are either constant (effective elimination half-life, total plasma clearance, and dose-normalized area under the plasma concentration-time curve) or varying proportionally (trough plasma concentration, peak plasma concentration, average plasma concentration and the area under the plasma concentration-time curve for a dosage interval at steady state) with the doses. The linear 1-compartment open model with zero-order absorption was the most appropriate pharmacokinetic model describing the raclopride plasma concentration profile after a single 8 mg dose of raclopride ER capsules. The ER formulation reduced the fluctuation between peak and trough plasma drug concentrations which has been reported before with instant release dosage forms. In this study, the increase of plasma prolactin concentrations above the normal limit was transient and returned to normal levels. Although the plasma prolactin concentration tended to increase with the drug dose, no direct relationship between raclopride dose and prolactin plasma concentrations was found. The correlation of plasma prolactin response with the plasma raclopride concentration showed a low level of hysteresis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647082      PMCID: PMC1188704     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  18 in total

1.  Akathisia with haloperidol and thiothixene.

Authors:  T Van Putten; P R May; S R Marder
Journal:  Psychopharmacol Bull       Date:  1984

2.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.

Authors:  C Köhler; H Hall; S O Ogren; L Gawell
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

3.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

4.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

5.  Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial.

Authors:  J C Cookson; B Natorf; N Hunt; T Silverstone; G Uppfeldt
Journal:  Int Clin Psychopharmacol       Date:  1989-01       Impact factor: 1.659

6.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

7.  Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography.

Authors:  L Farde; E Ehrin; L Eriksson; T Greitz; H Hall; C G Hedström; J E Litton; G Sedvall
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males.

Authors:  L Farde; C von Bahr; A Wahlen; L Nilsson; M Widman
Journal:  Int Clin Psychopharmacol       Date:  1989-04       Impact factor: 1.659

9.  An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.

Authors:  L Farde; F A Wiesel; P Jansson; G Uppfeldt; A Wahlen; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.

Authors:  S O Ogren; H Hall; C Köhler; O Magnusson; S E Sjöstrand
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more
  3 in total

Review 1.  A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 2.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

3.  The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors.

Authors:  Angelika Schedel; Patrick Schloss; Harald Klüter; Peter Bugert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-10       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.